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Objectives: To investigate the mechanism of action at the molecular level of pepR, a multifunctional peptide
derived from the Dengue virus capsid protein, against Staphylococcus aureus biofilms.
Methods: Biofilm mass, metabolic activity and viability were quantified using conventional microbiology techni-
ques, while fluorescence imaging methods, including a real-time calcein release assay, were employed to inves-
tigate the kinetics of pepR activity at different biofilm depths.
Results: Using flow cytometry-based assays, we showed that pepR is able to prevent staphylococcal biofilm for-
mation due to a fast killing of planktonic bacteria, which in turn resulted from a peptide-induced increase in the
permeability of the bacterial membranes. The activity of pepR against pre-formed biofilms was evaluated
through the application of a quantitative live/dead confocal laser scanning microscopy (CLSM) assay. The results
show that the bactericidal activity of pepR on pre-formed biofilms is dose and depth dependent. A CLSM-based
assay of calcein release from biofilm-embedded bacteria was further developed to indirectly assess the diffusion
and membrane permeabilization properties of pepR throughout the biofilm. A slower diffusion and delayed activ-
ity of the peptide at deeper layers of the biofilm were quantified.
Conclusions: Overall, our results show that the activity of pepR on pre-formed biofilms is controlled by its diffu-
sion along the biofilm layers, an effect that can be counteracted by an additional administration of peptide. Our
study sheds new light on the antibiofilm mechanism of action of antimicrobial peptides, particularly the import-
ance of their diffusion properties through the biofilm matrix on their activity.
Introduction
Bacterial infections are a major human health problem given not
only the increasing incidence of drug-resistant bacteria and the
decreased search for new antibiotics,1,2 but also due to the ability
of bacteria to form biofilms.3,4 Bacterial biofilms are surface-
associated bacterial communities embedded in a matrix of extra-
cellular polymeric substances (EPSs) that are implicated in the ma-
jority of human bacterial infections.3,5–7 Staphylococcus aureus, a
Gram-positive bacterium, is a human pathogen commonly involved
in biofilm-related infections such as chronic wound infections and
medical device-associated infections.8–10 The treatment of this
type of infection is difficult because biofilm-associated bacteria are
more tolerant to conventional antibiotics than their planktonic
counterparts.11,12 It is thus urgent to develop novel antimicrobial
agents designed to be active against bacterial biofilms.
Antimicrobial peptides (AMPs) are a group of molecules that
can be found in all life domains and are known for their activity
against Gram-positive and Gram-negative bacteria, viruses and
fungi.13 Although diverse in their amino acid sequences, they
are usually small, cationic and amphipathic. AMPs have been
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considered potential alternatives to conventional antibiotics14,15
and, more recently, a promising option against bacterial bio-
films.16,17 Over the years, studies conducted using mostly bacteria
in the planktonic state have shown that AMPs have a broad-
spectrum, fast bactericidal activity and membrane-targeting
mechanism of action13,15 which makes them good candidates
to develop new antibiofilm agents.18–21 Unlike conventional antibi-
otics with specific targets, almost exclusively proteins or nucleic
acids in metabolically active bacteria, AMPs act mainly through
bacterial membrane disruption, which makes them potentially
active against slow-growing or non-growing biofilm cells. While
the ability of AMPs to act on bacterial biofilms has been
addressed,18,19,21 a thorough and consistent focus on the study
of their antibiofilm action at the molecular level is desirable to
expand the potential use of AMPs as antibiofilm agents and thus
endow anti-infective drug development pipelines.
In the quest for new antimicrobial agents we have recently
shown the potential of structural viral proteins, particularly viral
capsid proteins, as a source for peptides with antibacterial proper-
ties against both Gram-positive and Gram-negative bacteria.22,23
Interestingly, some of these viral-derived peptides also exhibit
cell-penetrating properties that confer potential use on intracellu-
lar bacterial targets. One of those peptides, pepR, a synthetic pep-
tide whose sequence corresponds to amino acid residues 67–100
from Dengue virus capsid protein, was reported to be active
against Gram-positive and Gram-negative bacteria in the plank-
tonic form.22 Here, we show that pepR is able to both prevent and
act on S. aureus biofilms. As such, we have used pepR as a model
antibacterial peptide to investigate in detail the molecular mech-
anism underlying its antibiofilm actions. Using a combination of
confocal fluorescence microscopy assays, the spatiotemporal pro-
file of pepR activity against mature S. aureus biofilms has been
investigated. Our studies highlight the importance of pepR slow
diffusion through the extracellular matrix in controlling its killing
efficacy at the inner layers of the biofilms.
Materials and methods
Materials and methods are described only briefly here. Further details are
provided as Supplementary data (available at JAC Online).
pepR synthesis
pepR, LKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR-amide,24 was synthe-
sized using solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) chemistry25
and purified using HPLC as previously described.26 pepR stock solutions
were prepared in sterile Milli-Q water at 1 or 2 mM and stored at#20C. The
2-fold serial dilutions of pepR used in the different assays were prepared in
Mueller–Hinton broth (MHB), except when otherwise specified.
Bacterial strain and growth conditions
S. aureus strain ATCC 6538 was obtained from the ATCC (Manassas, VA,
USA). Bacteria were grown in MHB from BD (Franklin Lakes, NJ, USA) at
37C. S. aureus bacterial biofilms were prepared in tryptic soy broth (TSB),
also from BD, containing 0.25% (w/v) glucose (TSBG) for 24 h at 37C.
Antibacterial and bactericidal activities on planktonic
bacterial cells
MIC and MBC were determined using a broth microdilution method27,28 as
previously described.23
Inhibition of biofilm formation
Two-fold serial pepR dilutions covering the 0.78–50 lM range were directly
added to S. aureus suspensions prepared at 1%106 cfu/mL in MHB.
Untreated bacterial suspensions were used as a control. Each suspension
was dispensed into a 96-well microtitre flat-bottomed polystyrene plate
(200mL/well) and incubated at 37C for 24 h. After incubation, bacterial
metabolic activity was assayed using a resazurin reduction fluorometric
assay, and the biomass produced was evaluated using a crystal violet (CV)
assay.
Effect on established biofilms
S. aureus (1%106 cfu/mL) were cultured in TSBG and incubated in 96-well
microtitre flat-bottomed polystyrene plates for 24 h at 37C to allow for bio-
film formation. Non-adherent bacteria were then washed out with MHB,
and 2-fold serial pepR dilutions (0.78–100lM) were added to the biofilms
for 24 h. Untreated 24 h-pre-formed biofilms were used as a control. The
metabolic activity of biofilm cells was determined using a resazurin reduc-
tion fluorometric assay, and cell viability was measured using a colony
count assay.
Bacterial killing kinetics
The kinetics of the bactericidal effect of pepR on both planktonic and
biofilm forms of S. aureus was determined using a colony count-based
method.29,30 S. aureus suspensions prepared at 5%105 cfu/mL on MHB or
24 h-pre-formed biofilms grown in TSBG were treated with increasing con-
centrations of pepR and incubated for different amounts of time at 37C
(and 200 rpm for the bacterial suspensions). Untreated bacterial suspen-
sions/biofilms prepared under the same experimental conditions were
used as a control. At chosen timepoints, the colony count assay was
performed. Viable bacteria (in cfu/mL) are reported as a percentage of the
untreated control.
Membrane permeabilization of planktonic bacteria
The ability of pepR to induce membrane permeabilization of S. aureus in the
planktonic form was correlated with the concomitant loss of cell viability by
performing a flow cytometric analysis of the SYTOX Green uptake assay in
conjunction with a colony count assay as previously described23 with minor
modifications.
Live/dead fluorescence imaging of S. aureus biofilms
using confocal laser scanning microscopy (CLSM)
The visualization of the progressive loss of cell viability at different depths
of the biofilm-embedded bacteria due to pepR action was achieved by
implementing an adapted live/dead assay using SYTO 9 and TO-PRO-3 iod-
ide (Molecular Probes, Eugene, OR, USA) as the green and red fluorescent
nucleic acid-binding dyes, respectively, after introducing some modifica-
tions to a previously described31 procedure.
CLSM-based calcein release assay
The ability of pepR to permeabilize the bacterial membrane of S. aureus
biofilm-embedded cells was evaluated using a CLSM-based calcein release
assay adapted from the literature.32
Statistical analysis
Data are presented as mean+ standard deviation of three independent









/jac/article/74/9/2617/5498604 by Faculdade de M
edicina de Lisboa user on 11 January 2022
Results and discussion
pepR is able to both prevent the formation of and act on
pre-formed S. aureus biofilms
pepR is a highly cationic, viral-derived peptide known for its anti-
bacterial activity against both Gram-positive and Gram-negative
planktonic bacteria. Here, we focused on studying the activity and,
most importantly, the mechanism of action of pepR against bio-
films of S. aureus, one of the most common pathogens responsible
for biofilm-related infections.8,9pepR was able to prevent the for-
mation of S. aureus biofilms (Figure 1a). The biofilm mass, eval-
uated using a CV assay, after 24 h incubation of planktonic bacteria
with the peptide, was maximally reduced at 6.25mM pepR. This
closely matched the parallel drop detected in the metabolic activ-
ity of the bacterial cells as measured with a resazurin reduction
fluorometric kinetic assay. The inhibition of biofilm formation
by pepR was due to a direct effect of the peptide on planktonic
S. aureus, since pepR displayed high antibacterial activity against
the S. aureus ATCC 6538 with an MIC of 3.1mM and an MBC within
the 3.1–12.5mM range. pepR also exhibited a fast killing of
planktonic S. aureus (Figure 1b), which in turn resulted from the
peptide-induced increase in the permeability of the bacterial
membranes, as shown using a flow cytometric-based detection of
cellular uptake of SYTOX Green dye (Figure 1c and d).
The activity of pepR against biofilms was further evaluated by
testing its ability to act on established biofilms as these are more
challenging to eradicate. The effect of pepR on 24 h-pre-formed
S. aureus biofilms was investigated by exposing the biofilms to
increasing concentrations of peptide for 24 h. A colony count and
resazurin reduction fluorometric kinetic assay (Figure S1) concur-
rently showed that pepR is able to act on pre-formed biofilms in a
dose-dependent fashion, reaching a maximum efficiency at
50lM (Figure 2a). As expected, the pepR-induced killing kinetics
of the biofilm-embedded cells were slower when compared with
the planktonic bacteria, reaching a plateau after 2 h incubation of
the pre-formed biofilm with pepR, as exemplified in Figure 2(b)
for 25 and 50mM pepR. In fact, the reduction in the percentage of


























































0.01 0.1 1 10 100
























Figure 1. pepR prevents S. aureus biofilm formation through a bactericidal activity caused by membrane permeabilization of planktonic cells. (a)
pepR inhibits S. aureus biofilm formation. Planktonic bacterial cells were incubated for 24 h at 37C with increasing concentrations of pepR. The meta-
bolic activity and the biofilm biomass of untreated and pepR-treated bacterial cells were evaluated using a resazurin reduction fluorometric kinetic
assay (resazurin reduction, % of control, open circles) and a CV binding assay (DAbs590 nm, % of control, filled squares), respectively. The increase in
CV staining detected upon increasing the pepR concentration above 6.25mM was independently confirmed to be due to non-specific binding of CV to
the peptide directly adsorbed onto the bare polystyrene microplate surface. (b) pepR induces fast killing kinetics of planktonic S. aureus. The time–kill
of planktonic bacterial cells by different concentrations of pepR was evaluated using a colony count assay. Viable bacteria (in cfu/mL) are reported as
a percentage of the untreated sample. (c and d) The pepR-induced loss of cell viability is inversely correlated with membrane permeabilization of
S. aureus planktonic cells. (c) Illustrative histogram analysis of the bacterial populations after exposure to variable concentrations of pepR for 1 h that
were monitored using a flow cytometric analysis of SYTOX Green uptake by the planktonic bacteria. (d) The fractions of permeabilized bacterial cells
(filled squares) and viable bacteria (in cfu/mL, filled circles) are reported as a percentage of the untreated sample.
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pepR was found to be very similar after 2 or 24 h treatment for all
the concentrations of pepR tested (Figure 2a).
The bactericidal activity of pepR on pre-formed
S. aureus biofilms is depth dependent
To directly visualize and quantify the bactericidal activity of pepR
on 24 h-pre-formed S. aureus biofilms at different biofilm depths,
we performed a live/dead CLSM-based study using SYTO 9 and
TO-PRO-3 iodide as the nucleic acid-binding dyes. SYTO 9 is a
membrane-permeable dye that stains all bacteria green (with in-
tact and damaged membranes) in a population, whereas TO-PRO-
3 iodide only penetrates and stains red any bacteria with damaged
membranes.31,33
Representative CLSM images obtained at an inner layer
(z"1.5mm, z being the distance from the surface of the glass slide)
of 24 h-pre-formed biofilms which were untreated or treated with
25 or 50 lM pepR for 2 h, and then sequentially stained with SYTO
9 and TO-PRO-3 iodide, are presented in Figure 3(a). Treatment of
pre-formed biofilms with increasing concentrations of pepR pro-
duced a clear increase in the red-stained circular aggregates with
high fluorescence intensity (Figure S2) and a concomitant reduc-
tion of bacteria stained with SYTO 9 (left panels of Figure 3a, SYTO
9 and TO-PRO-3 iodide, x–y plane images). This double opposing
effect registered in the green and red channels of the CLSM x–y
plane images confirms the ability of pepR to kill biofilm-associated
bacteria through the disruption of their membranes.
Quantification of the degree of co-localization between the two
fluorescent dyes was achieved by colour scatter plots and calcula-
tion of the Pearson’s correlation coefficient (PCC).34 As shown in
the central panels of Figure 3(a) (overlay, x–y), their corresponding
scatter plots suggest that TO-PRO-3 iodide enters the biofilm-
embedded bacteria upon pepR-induced membrane damage, par-
tially displacing the intracellular DNA (iDNA)-bound SYTO 9 dye due
to a competition effect. This causes the membrane-compromised
bacteria to appear orange in both the x–y and x–z overlay plots
(Figure 3a). The average PCC value for the untreated and 50 lM
pepR-treated double-stained biofilms at z"1.5mm were
PCC"#0.06+0.16 and PCC"0.78+0.04, respectively (Figure 3b),
which essentially correspond to an observation field with all the
bacteria with either an intact or compromised plasma membrane,
respectively. Interestingly, the PCC values obtained at this biofilm
depth for the double-stained pre-formed biofilms treated with the
intermediate concentration of 25 lM pepR presented a bimodal
distribution, with the observation fields containing either predom-
inantly membrane-intact (PCC"#0.03+0.15) or membrane-
compromised bacteria (PCC"0.59+0.12). As we move away from
the coverslip [i.e. from an inner (z"1.5mm) to an outer (z"10.5mm)
biofilm layer] (Figure S3), the cellular density of the untreated bio-
films becomes more rarefied and their corresponding PCC
value slightly increases from PCC(z"1.5mm)"–0.09+0.14 to
PCC(z"7.5 lm)"0.07+0.11, and finally to PCC(z"10.5mm)
"0.16+0.09 (Figure 3c). This result most probably reflects the sim-
ultaneous binding of both fluorescent dyes to the extracellular
DNA (eDNA), which is more abundant at the outer compared with
the inner biofilm layer. Interestingly, an analogous analysis of the
biofilms treated for 2 h with 25mM pepR reveals that the bimodal
distribution of PCC values detected at z"1.5mm (PCC"0.06+0.10
and PCC"0.51+0.09) progressively shifts to an unimodal distribu-
tion with PCC"0.63+0.17 at z"10.5mm (Figure 3c), revealing that
the bacterial membranes of the biofilm-embedded bacteria at the
periphery of the biofilm are more uniformly and reproducibly com-
promised by pepR action compared with an inner layer.
pepR antibiofilm properties are controlled by its
diffusion along the biofilm matrix
The above data strongly suggest that the biofilm matrix is acting
as a barrier that reduces/slows down the penetration of pepR, with
a consequent decrease in activity at the more deeply biofilm-
embedded bacterial cells. To obtain a clearer picture of the spatio-
temporal profile of pepR activity, we next sought to investigate the
time dependence of its action at different biofilm depths. A real-
time CLSM assay of calcein release from CAM-pre-loaded 24 h-pre-
formed S. aureus biofilms was developed to indirectly assess
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Figure 2. pepR acts on pre-formed S. aureus biofilms in a concentration- and time-dependent manner. (a) Effect of pepR on the viability of S. aureus
biofilm-associated cells. 24 h-pre-formed biofilms were incubated for 2 h or 24 h at 37C with increasing concentrations of pepR. The metabolic activ-
ity of untreated and pepR-treated bacterial cells for 24 h was measured using a resazurin reduction fluorometric kinetic assay (resazurin reduction, %
of control, open circles); bacterial viability after 2 h (red filled triangles) or 24 h (blue filled triangles) pepR treatment was also evaluated using a colony
count assay (cfu/mL, % of control). (b) The time–kill of biofilm-embedded bacteria induced by 25 and 50 lM pepR was evaluated using a colony count
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throughout the biofilm over time32 (Figure 4a). CAM is a non-
fluorescent calcein derivative that passively diffuses across plasma
membranes; once inside the cytoplasm, CAM is hydrolysed by
cytoplasmic esterases, releasing highly fluorescent calcein.35 Due
to its anionic character, calcein is retained in live cells with intact
membranes;32,35 damage to membrane integrity induces calcein
release from the bacterial cells and its subsequent dilution into
the extracellular media, causing a decrease in the fluorescence in-
tensity. The corresponding kinetics (cellular uptake and leakage
of the dye, respectively) from biofilm-embedded bacteria can
therefore be monitored by measuring the relative changes in the
fluorescence intensity of calcein over time at different biofilm
depths using CLSM.
Illustrative time-lapsed x–z vertical slice images of 24 h-pre-
formed S. aureus biofilms pre-loaded with CAM during an
incubation period of 3 h and then left untreated or treated
with pepR at 50 mM for 2 h are presented in Figure 4(b). A
first quantitative analysis of these images was performed by
evaluating the relative changes over time in the average fluor-
escence emission intensity from a rectangular region of interest
(ROI) encompassing the calcein-stained pre-formed biofilms.
Figure 4(c) shows that pepR induced a monoexponential decay
of the average calcein fluorescence emission intensity over the
2 h incubation with t1=2"23 min. On the other hand, the average
fluorescence emission intensity of calcein-pre-loaded biofilms
left untreated slightly increased during the same time period,
possibly due to residual CAM hydrolysis by the intact biofilm-
embedded bacteria. This result rules out that significant spon-
taneous calcein leakage is occurring during the assay or that
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Figure 3. CLSM-based analysis of the influence of pepR concentration and biofilm depth on the pepR-induced decrease in the viability of biofilm-
embedded bacteria. (a) Representative CLSM images of 24 h-pre-formed biofilms untreated and pepR treated for 2 h; the biofilms were stained with
the nucleic acid-binding dyes SYTO 9 and TO-PRO-3 iodide. SYTO 9 passively diffuses across intact cell membranes and binds to the iDNA; TO-PRO-3
iodide is excluded from cells with structurally intact membranes and can only bind the iDNA of membrane-compromised bacteria. The left panels cor-
respond to x–y plane images taken at the inner layer of S. aureus stained biofilms (z"1.5 mm). The overlay of the green and red channels from the x–y
and x–z orthogonal plane images is presented in the central and right panels, respectively. The extent of fluorophore co-localization can be evaluated
from the central scatter plots; the PCC was quantified using the WCIF ImageJ software. (b and c) The degree of co-localization between SYTO 9 and
TO-PRO-3 iodide varies with (b) the pepR concentration used at an inner biofilm layer (z"1.5 mm) and (c) the biofilm depth, z, in the presence of 25 mM
pepR [untreated (filled circles) and pepR-treated (filled triangles) pre-formed S. aureus biofilms].
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Figure 4. Time-lapsed CLSM-based imaging study of the pepR-induced calcein release from biofilm-embedded bacteria. (a) Top panel: the non-fluor-
escent derivative of calcein, CAM, can be taken up by the cells through passive diffusion across their plasma membranes; once inside the cytoplasm,
CAM is readily hydrolysed by cytoplasmic esterases, releasing calcein, a highly fluorescent compound. The pepR-induced increase in cell membrane
permeability causes the subsequent release and dilution of calcein in the medium. Bottom panels: representative calcein uptake (left panel) and re-
lease (right panel) kinetics for 24 h-pre-formed S. aureus biofilms incubated with CAM over 3 h and then treated with pepR for an additional period of
2 h. (b) Illustrative time-lapsed CLSM images of calcein release from untreated and pepR-treated 24 h-pre-formed biofilms. Orthogonal views to the
S. aureus biofilms surface (xzy sections) were taken every 10 min for a total of 2 h. (c) Relative changes in the average calcein fluorescence intensity
(FI) from a pre-defined rectangular ROI encompassing the untreated (filled triangles) and pepR-treated (filled circles) calcein-stained biofilms over
time. The relative FI values are the mean+ SD of five independent experiments. A mono-exponential decay by non-linear regression (solid line) was
fitted to the data obtained for the pepR-treated samples. (d) Illustrative influence of biofilm depth on the calcein release kinetics from untreated (tri-
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A more detailed analysis of the data allowed identification of
different spatiotemporal patterns of fluorescence loss when the
calcein-pre-loaded biofilms were exposed to pepR (Figure S4). The
data obtained at two representative biofilm depths are plotted in
Figure 4(d). This figure shows that at a biofilm depth close to the
interface between the biofilm and the bulk fluid (z"10mm), pepR
caused a relatively fast and complete loss of calcein fluorescence
emission intensity. However, at an inner layer of the biofilm nearer
the coverslip surface (z"3mm), a clear lag time of 30 min was
detected before the relative change in the fluorescence signal
from calcein started to decrease towards a limiting value of20%
after a 2 h incubation. These results can be ascribed to the progres-
sive diffusion/binding of pepR through the biofilm matrix. In order
to obtain an estimate for the diffusion coefficient of the peptide, a
simple model describing the time and depth dependence of the
diffusion of pepR throughout the biofilm matrix was derived by
assuming that the calcein fluorescence emission intensity tends to
zero over space and time (Supplementary Equation 4 in the
Supplementary data). As illustrated in Figure 5(a), this model ad-
equately fitted the experimental data obtained from the periph-
eral biofilm layers [from d"3.5mm to d"11mm (Figure 5b), where
d is now the distance from the biofilm interface to the aqueous so-
lution], and the globally fitted diffusion coefficient obtained for
pepR was Dbiofilm"4.5%10
#3 lm2 s#1. This value is several orders
of magnitude lower than the expected diffusion coefficient for a
random-coiled peptide with a molecular weight of 4.3 kDa that is
freely diffusing in aqueous solution at room temperature
(Dsolution"140 lm
2 s#1,36 and is typical of large charged molecules
diffusing in dense media such as the cell nucleus.37 Such a slow dif-
fusion of pepR can be ascribed to the high viscosity of the EPS ma-
trix38 and the establishment of electrostatic interactions between
the highly cationic peptide (net charge !13 at physiological pH)
and the negatively charged polyelectrolytes of the EPS matrix.39
Other effects, such as ‘corralling’ and the presence of obstacles
hindering free diffusion,40,41 may also contribute to slow molecular
progression of pepR within the biofilm. For comparison, a similar
although not so pronounced effect has already been described for
the smaller fluorescently labelled antibiotic vancomycin-BODIPY
(1.7 kDa and net charge 0.7 at physiological pH), as its diffusion
was found to be much slower through a biofilm matrix compared




pepR progressive diffusion into the extracellular matrix
controls its availability and antibiofilm activity
The data presented in Figure 2 show that 15%–20% of biofilm-
embedded bacteria survived a single peptide treatment, after 24 h
incubation. On the other hand, both the live/dead and the calcein
release CLSM-based studies revealed that the pepR-induced in-
crease in membrane permeability is strongly dependent on the
biofilm depth. Two main factors may be responsible for these
effects: (i) the majority of pepR added in a single dose interacts
with the biofilm matrix components, reducing the amount of free
peptide available to reach the inner layers of the biofilm; or (ii) a
subpopulation of bacteria resistant to peptide treatment is present
at the inner layers of the biofilm. In the first case, we reasoned that
if pepR interacts with the biofilm matrix components, nearly reach-
ing its saturation limit after the first treatment, then the addition
of a second dose of peptide should allow this effect to be over-
come due to the increased availability of free peptide. To test this
hypothesis, we performed an experiment where 24 h-pre-formed
S. aureus biofilms were first treated for 24 h with 50mM pepR
(Figure 6, left); the pre-treated biofilms were then exposed to a se-
cond peptide dose of 25 or 50mM. The results revealed a pro-
nounced increase in the killing efficacy of the peptide with the
second dose, as the percentage of bacterial survival decreased
from 20% (Figure 6, left) with the first treatment to 3%–4% with
the second treatment (Figure 6, middle left). To further validate
these results and discard the second hypothesis, additional experi-
ments were performed. First, 24 h-pre-formed S. aureus biofilms
were treated for 24 h with 50mM pepR. Then, these pre-treated
biofilm cells were washed, re-suspended (108 cfu/mL) and
exposed to a second peptide dose of 25 or 50mM. The results
showed a percentage of bacterial survival of 0.5%–1% (Figure 6,
middle right), which is similar to what was obtained when the cells
in the biofilm form were directly treated sequentially with two
doses of pepR (Figure 6, middle left). In addition, we found that the
killing efficacy of pepR was very similar when the same concentra-
tions of the peptide were directly added to a high bacteria inocu-
lum (bacteria in planktonic form that have not gone through a
biofilm stage) (Figure 6, right). Altogether, these results rule out


























Figure 5. pepR action on biofilm-embedded bacteria is strongly diffusion
controlled. (a) Representative data illustrating the relative changes in
the fluorescence emission intensity of calcein over time and biofilm dis-
tance from the interface after pepR addition to a pre-formed calcein-
stained biofilm. Supplementary Equation 4 was used to globally fit the
data obtained at 17 different biofilm distances, d, from the interface.
Solid lines illustrate the global best fit solution to five of these data sets,
from which D"4.5%10#3 lm2 s#1 and Kapp"4.1%10
#1lM#1 were
retrieved. (b) Illustrative 2D image of a calcein-loaded biofilm (pseudo-
coloured in green). The red shaded area highlights the peripheral biofilm
area that was analysed using Supplementary Equation 4. The roughness
of the biofilm interface was taken into account in this analysis as shown
here.
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biofilm layers are adaptively resistant to peptide treatment, and
strongly support the conclusion that there is a graded activity of
pepR along distinct biofilm layers, which in turn is caused by the
development of a concentration gradient of pepR along its depth
due to its strong interaction with matrix components. Once pepR
interaction with the extracellular matrix is close to saturation, the
administration of a new peptide dose results in a pronounced in-
crease in its killing efficacy because the peptide is now able to
slowly reach the inner biofilm layers at a concentration above the
threshold controlling the pepR-induced increase in membrane
permeability.
Taken together, these results support the conclusion that bio-
film treatment with sequential doses of an AMP is a valid strategy
to increase its overall killing efficacy. Another useful approach al-
ready proposed in the literature involves using AMPs in combin-
ation with other antibacterial agents to produce a synergistic
effect, and therefore improve their activity against biofilms.43
These could include the use of enzymes capable of disrupting the
extracellular matrix and therefore facilitating AMP activity against
biofilm-associated cells.44,45
Conclusions
We have used pepR, a peptide derived from the Dengue virus cap-
sid protein, as a model to study in detail the antibiofilm action of
an antibacterial peptide at the molecular level. Importantly, we
showed that pepR has dual activity, acting both as an antimicrobial
and as an antibiofilm molecule. pepR was found to exert a fast
bactericidal activity on planktonic S. aureus cells, thus preventing
biofilm formation. On the other hand, the spatiotemporal patterns
of pepR-induced killing of biofilm-embedded bacteria showed that
pepR activity on pre-formed biofilms was strongly diffusion
controlled, causing delayed killing at the inner biofilm layers. pepR
diffusion through the biofilm matrix is possibly dictated by the
high viscosity of the medium, ‘corralling’ and the establishment of
electrostatic interactions with the anionic matrix. Biofilm treat-
ment with sequential doses of pepR resulted in more efficient kill-
ing of biofilm cells, highlighting that the inner biofilm layers do not
consist of bacteria adaptively resistant to peptide treatment.
Taken together, these results shed light on the effect of the biofilm
matrix on the diffusion of antibacterial molecules and its influence
on their activity.
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(FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) (projects
PTDC/QEQ-MED/4412/2014, FAPESP/20107/2014, SAICTPAC/0019/2015,
PPBI-POCI-01-0145-FEDER-022122); by the Spanish Ministry of Economy
and Competitiveness (MINECO) (grant AGL2014-5239-C2-2R); and by the
Marie Skłodowska-Curie Research and Innovation Staff Exchange (grant
H2020-MSCA-RISE-2014–644167). We also acknowledge project UID/BIM/
50005/2019, funded by FCT/MCTES through Fundos do Orçamento de
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